Buildit, Finished listening to the call. I ca
Post# of 36536
(Total Views: 332)
Posted On: 02/05/2021 5:30:16 PM
Buildit,
Finished listening to the call. I can’t disagree with anything you said.
Seemed to be an issue on taking questions. Technical? The operator did say press *1. Did everyone press * first before 1?
Joe did kill the “buzz” with the preemptive “quiet period” comment. For more info on quiet periods: https://www.securitieslawyer101.com/2020/form...d%2C%20the
Joe mentioned 3 S-1s each for GNBT and NGIO. Not sure what the GNBT S-1s were about since they involve adding more shares to the float. Maybe AltuCell? From the last 10-Q:
ALTuCELL
On November 22, 2019, the Company entered into a Stock Purchase Agreement (“SPA”) for the purchase of 51% of the outstanding capital stock of GH Care, Inc. DBA ALTuCELL, Inc.(“ALTuCELL”).
Under the SPA, in exchange for the ALTuCELL Stock, Generex will issue to ALTuCELL 2,240,000 shares of Generex common stock with an attributed value of $4 million to be issued at the market price of the day at closing, but no less than $0.89 per share.
As Doc mentioned, new NGIO update evaluation requires an S-1 update.
Did like that Ii-key has/will be able to provide fast results on Covid variants
That the Phase1/2 materials will be shipped to China for trial immediately after these last test (mouse?) results.
Phase 1/2 only require a small set of test subjects, 10k or less.
The pps will take care of itself. About 1.5 million shares sold at or above $.50/share. Probably the same 1.5 million re-bought at the low $.40s level. With almost 4 million total volume for today, that leaves about a million shares hopefully bought by new “long haulers”. If we can get a +$.60 support for next week, it might prove my analysis is correct.
Finished listening to the call. I can’t disagree with anything you said.
Seemed to be an issue on taking questions. Technical? The operator did say press *1. Did everyone press * first before 1?
Joe did kill the “buzz” with the preemptive “quiet period” comment. For more info on quiet periods: https://www.securitieslawyer101.com/2020/form...d%2C%20the
Joe mentioned 3 S-1s each for GNBT and NGIO. Not sure what the GNBT S-1s were about since they involve adding more shares to the float. Maybe AltuCell? From the last 10-Q:
ALTuCELL
On November 22, 2019, the Company entered into a Stock Purchase Agreement (“SPA”) for the purchase of 51% of the outstanding capital stock of GH Care, Inc. DBA ALTuCELL, Inc.(“ALTuCELL”).
Under the SPA, in exchange for the ALTuCELL Stock, Generex will issue to ALTuCELL 2,240,000 shares of Generex common stock with an attributed value of $4 million to be issued at the market price of the day at closing, but no less than $0.89 per share.
As Doc mentioned, new NGIO update evaluation requires an S-1 update.
Did like that Ii-key has/will be able to provide fast results on Covid variants
That the Phase1/2 materials will be shipped to China for trial immediately after these last test (mouse?) results.
Phase 1/2 only require a small set of test subjects, 10k or less.
The pps will take care of itself. About 1.5 million shares sold at or above $.50/share. Probably the same 1.5 million re-bought at the low $.40s level. With almost 4 million total volume for today, that leaves about a million shares hopefully bought by new “long haulers”. If we can get a +$.60 support for next week, it might prove my analysis is correct.
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼